中医临床研究2026，Vol.18Issue(4)：65-70,6.DOI:10.3969/j.issn.1674-7860.2026.04.010
筋骨痛消丸靶向Src通路改善骨关节炎的机制探讨
Mechanistic investigation of Jinggu Tongxiao Wan in improving osteoarthritis by targeting the Src pathway
摘要
Abstract
Objective:To study the mechanism of action of Jinggu Tongxiao Wan(筋骨痛消丸)in ameliorating osteoarthritis.Methods:Human chondrosarcoma cells line SW1353 were induced by lipopolysaccharide(LPS)and then cultured in high,medium and low concentrations of Jinggu Tongxiao Wan drug-containing serum as well as PP2 chemical inhibitors,respectively.Cell viability and its related markers,including VEGF level and expression of SOX9 and Src proteins were detected by CCK-8,ELISA and immunofluorescence staining,respectively.Results:LPS induction inhibited SW1353 cells viability,promoted VEGF secretion,upregulated Src expression,and downregulated SOX9 expression.In contrast,intervention with the drug-containing serum of Jinggu Tongxiao Wan and PP2 enhanced cell viability suppressed VEGF secretion,reduced Src expression,and correspondingly increased SOX9 expression.Moreover,with the increase in the concentration of the drug-containing serum,cell viability was enhanced,VEGF secretion were decreased,Src expression was increased first and then was decreased,and SOX9 expression was elevated.Conclusion:The drug-containing serum of Jinggu Tongxiao Wan inhibits the angiogenesis of blood vessels by suppressing VEGF,thereby blocking the Src signaling pathway and promoting the expression of SOX9,ultimately suppressing osteoarthritis.关键词
筋骨痛消丸/骨关节炎/Src酪氨酸蛋白激酶/血管内皮生长因子Key words
Jinggu Tongxiao Wan/Osteoarthritis/Src protein tyrosine kinase/Vascular endothelial growth factor分类
医药卫生引用本文复制引用
孙瑞,夏华玲,陈宝龙,杨昭杰,郭继锋,冯坤,谢文..筋骨痛消丸靶向Src通路改善骨关节炎的机制探讨[J].中医临床研究,2026,18(4):65-70,6.基金项目
2023年河南省中医药研究专项课题资助(2023ZY2133). （2023ZY2133）
